Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the US Ending the HIV Epidemic jurisdictions

被引:29
|
作者
Sullivan, Patrick S. [1 ]
Mouhanna, Farah [2 ,4 ]
Mera, Robertino [3 ]
Pembleton, Elizabeth [1 ]
Castel, Amanda D. [2 ]
Jaggi, Chandni [1 ]
Jones, Jeb [1 ]
Kramer, Michael R. [1 ]
McGuinness, Pema [1 ]
McCallister, Scott [3 ]
Siegler, Aaron J. [4 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
[2] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Epidemiol, Washington, DC USA
[3] Gilead Sci, Foster City, CA USA
[4] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA
关键词
HIV prevention; HIV pre-exposure prophylaxis; Pharmacy data; UNITED-STATES; ANTIRETROVIRAL PROPHYLAXIS; MEN; SEX; SURVEILLANCE; PREVENTION; INFECTION; RISK;
D O I
10.1016/j.annepidem.2020.01.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: Pre-exposure prophylaxis (PrEP) is a pillar of the US Department of Health and Human Services "Ending the HIV Epidemic" (EHE) initiative in 50 EHE jurisdictions (48 U.S. counties and two U.S. cities) and seven U.S. states with high numbers of HIV diagnoses rates in rural areas. Current data systems do not provide data on PrEP uptake in counties or cities. Methods: We report on PrEP users at the county level. Data from a large, commercial pharmacy database were used; we applied the U.S. Census Bureau's method to allocate PrEP users within a ZIP3 into counties and validated the results. We report counts and rates of PrEP users in 2018 for all EHE jurisdictions. We used joinpoint regression to model the estimated annual percent change in PrEP use for each jurisdiction and state. Results: 93,156 people in the 50 EHE jurisdictions used PrEP in 2018; 94% were men and 39% were aged 25-34 years. There was more than an 80-fold difference in the range of rates of PrEP use per 100,000 population among the EHE jurisdictions (range: 8-644 per 100,000 population; median 93 per 100,000 population). PrEP use increased from 2012 to 2018 in all EHE counties and states. At current rates of growth of PrEP use, 94% of EHE counties and jurisdictions will reach their National HIV/AIDS Strategy goals of a 500% increase in PrEP use in 2020. EHE states had less variation in rates of PrEP use (range: 29 -51/100,000 population; median 32/100,000 population). Conclusions: At the outset of a major U.S. government program to reduce HIV infections, rates of PrEP use are highly variable among the 50 EHE jurisdictions. Data from commercial prescription databases will be a useful public resource to understand progress in promoting use of PrEP as part of the EHE initiative and evaluating progress in PrEP use across health jurisdictions. (C) 2020 The Authors. Published by Elsevier Inc.
引用
收藏
页码:16 / 30
页数:15
相关论文
共 50 条
  • [1] Structural Racism and HIV Pre-exposure Prophylaxis Use in the Nationwide US: A County-Level Analysis
    Shi, Fanghui
    Mi, Tianyue
    Li, Xiaoming
    Ning, Huan
    Li, Zhenlong
    Yang, Xueying
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2024,
  • [2] Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018
    Siegler, Aaron J.
    Mehta, C. Christina
    Mouhanna, Farah
    Giler, Robertino Mera
    Castel, Amanda
    Pembleton, Elizabeth
    Jaggi, Chandni
    Jones, Jeb
    Kramer, Michael R.
    McGuinness, Pema
    McCallister, Scott
    Sullivan, Patrick S.
    ANNALS OF EPIDEMIOLOGY, 2020, 45 : 24 - +
  • [3] County-Level Factors Associated with Reversal of Insurer-Approved HIV Pre-Exposure Prophylaxis Prescriptions in the United States, 2018
    Rahel Dawit
    William C. Goedel
    Hsien-Yen Chang
    Amy S. Nunn
    Philip A. Chan
    Jalpa A. Doshi
    Lorraine T. Dean
    AIDS and Behavior, 2025, 29 (4) : 1089 - 1095
  • [4] HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic
    Rivera, Christina G.
    Zeuli, John D.
    Smith, Bradley L.
    Johnson, Tanner M.
    Bhatia, Ramona
    Otto, Ashley O.
    Temesgen, Zelalem
    DRUGS, 2023, 83 (18) : 1677 - 1698
  • [5] Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium
    Vanbaelen, Thibaut
    Rotsaert, Anke
    Jacobs, Bart K. M.
    Florence, Eric
    Kenyon, Chris
    Vuylsteke, Bea
    Laga, Marie
    Thijs, Reyniers
    AIDS PATIENT CARE AND STDS, 2022, 36 (04) : 159 - 167
  • [6] HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic
    Christina G. Rivera
    John D. Zeuli
    Bradley L. Smith
    Tanner M. Johnson
    Ramona Bhatia
    Ashley O. Otto
    Zelalem Temesgen
    Drugs, 2023, 83 : 1677 - 1698
  • [7] Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic
    Killelea, Amy
    Johnson, Jeremiah
    Dangerfield, Derek T.
    Beyrer, Chris
    McGough, Matthew
    McIntyre, John
    Gee, Rebekah E.
    Ballreich, Jeromie
    Conti, Rena
    Horn, Tim
    Pickett, Jim
    Sharfstein, Joshua M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2022, 50 : 8 - 23
  • [8] Changes in HIV Pre-exposure Prophylaxis (PrEP) Coverage at State and County Level During the COVID-19 Pandemic in the United States
    Mahdi Fallahi
    Jenny S. Guadamuz
    Andrew Shooshtari
    Dima M Qato
    AIDS and Behavior, 2024, 28 : 799 - 804
  • [9] Changes in HIV Pre-exposure Prophylaxis (PrEP) Coverage at State and County Level During the COVID-19 Pandemic in the United States
    Fallahi, Mahdi
    Guadamuz, Jenny S.
    Shooshtari, Andrew
    Qato, Dima M.
    AIDS AND BEHAVIOR, 2024, 28 (03) : 799 - 804
  • [10] Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention
    Patel, Rupa R.
    Mena, Leandro
    Nunn, Amy
    McBride, Timothy
    Harrison, Laura C.
    Oldenburg, Catherine E.
    Liu, Jingxia
    Mayer, Kenneth H.
    Chan, Philip A.
    PLOS ONE, 2017, 12 (05):